Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark

In this study, the authors use household data from Denmark to investigate the transmissibility of the BA.1 and BA.2 Omicron SARS-CoV-2 subvariants. They find that the secondary attack rate was higher for BA.2, but that it had higher infectiousness only when cases were not vaccinated.

Bibliographic Details
Main Authors:	Frederik Plesner Lyngse, Carsten Thure Kirkeby, Matthew Denwood, Lasse Engbo Christiansen, Kåre Mølbak, Camilla Holten Møller, Robert Leo Skov, Tyra Grove Krause, Morten Rasmussen, Raphael Niklaus Sieber, Thor Bech Johannesen, Troels Lillebaek, Jannik Fonager, Anders Fomsgaard, Frederik Trier Møller, Marc Stegger, Maria Overvad, Katja Spiess, Laust Hvas Mortensen
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-09-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-022-33498-0

Similar Items

Household transmission of the SARS-CoV-2 Omicron variant in Denmark
by: Frederik Plesner Lyngse, et al.
Published: (2022-09-01)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
by: Tomokazu Tamura, et al.
Published: (2023-07-01)

Omicron subvariant BA.5 efficiently infects lung cells
by: Markus Hoffmann, et al.
Published: (2023-06-01)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
by: Hung Fu Tseng, et al.
Published: (2023-01-01)

Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
by: Yu WU, Jue LIU, Min LIU, Wannian LIANG
Published: (2022-10-01)

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
by: Delphine Planas, et al.
Published: (2023-02-01)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
by: Mingxi Li, et al.
Published: (2022-12-01)

High Transmission Rates of Early Omicron Subvariant BA.2 in Bangkok, Thailand
by: Sininat Petcharat, et al.
Published: (2023-01-01)

Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou
by: Feng Li, et al.
Published: (2023-04-01)

Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes
by: Rayhane Nchioua, et al.
Published: (2022-12-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
by: Khadija Khan, et al.
Published: (2023-12-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
by: Aiste Dijokaite-Guraliuc, et al.
Published: (2022-11-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
by: Naoyuki Miyashita, et al.
Published: (2023-05-01)

Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study
by: Yuta Okada, et al.
Published: (2023-01-01)

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data
by: Antonio Russo, et al.
Published: (2024-01-01)

Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
by: Li-Teh Liu, et al.
Published: (2023-10-01)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
by: Jingyun Yang, et al.
Published: (2023-06-01)

Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding
by: Marko Popovic
Published: (2022-10-01)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
by: Alina Seidel, et al.
Published: (2023-04-01)

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.
by: Srilekha Sridhara, et al.
Published: (2023-01-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

The SARS-CoV-2 BA.2.86 subvariant: A new challenge in the ongoing pandemic
by: Prakasini Satapathy, et al.
Published: (2024-01-01)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
by: Xinling Wang, et al.
Published: (2023-11-01)

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
by: Jianpeng Cai, et al.
Published: (2024-12-01)

Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections
by: Bin Ju, et al.
Published: (2022-11-01)

Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants
by: Selene Zárate, et al.
Published: (2023-01-01)

Genomic architecture and evolutionary relationship of BA.2.75: A Centaurus subvariant of Omicron SARS-CoV-2.
by: Atia Basheer, et al.
Published: (2023-01-01)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022-12-01)

Statement on healthcare system preparedness in response to COVID-19 Omicron subvariants BA.4 and BA.5 surge in Korea from the Korean Pediatric Society and Korean Society of Pediatric Infectious Diseases
by: Eun Young Cho, et al.
Published: (2022-11-01)

Fusogenicity of SARS-CoV-2 BA.2.86 subvariant and its sensitivity to the prokaryotic recombinant EK1 peptide
by: Lijue Wang, et al.
Published: (2024-01-01)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
by: Freddy Dehesa-Canseco, et al.
Published: (2023-06-01)

Cryo-EM structures of SARS-CoV-2 BA.2-derived subvariants spike in complex with ACE2 receptor
by: Yaning Li, et al.
Published: (2023-11-01)

Whole-Genome Comparison of Representatives of All Variants of SARS-CoV-2, Including Subvariant BA.2 and the GKA Clade
by: Ida B. K. Suardana, et al.
Published: (2023-01-01)

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
by: Rafael R. G. Machado, et al.
Published: (2023-07-01)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
by: Freja Cordelia Møller Kirsebom, et al.
Published: (2022-12-01)

The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection
by: Dandan Tian, et al.
Published: (2022-10-01)

The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022
by: Yun Ling, et al.
Published: (2022-09-01)